The ADNI-Depression Project (ADNI-D)
The ADNI-Depression Project (ADNI-D) enrolled 120 participants who were experiencing symptoms of depression. The goal of the study is to determine whether imaging of the brain can help predict the onset and monitor the progression of cognitive change.
Memory Improvement Through Nicotine Dosing (MIND)
The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study is to determine whether daily transdermal nicotine (patch) will have a positive effect on early memory impairment in participants diagnosed with Mild Cognitive Impairment (MCI). We are looking for healthy, non-smoking adults, age 55+.
The LEARN Study
The LEARN study was funded by the Alzheimer’s Association to support the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study. The LEARN study is a companion study to the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study, a pioneering Alzheimer’s secondary prevention trial.
A4 Study
The landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 Study) enrolled 1,169 healthy older adults with normal memory but who might be at risk for Alzheimer’s due to family history of the disease and elevated levels of amyloid plaque in the brain. The primary study aims are to prevent the memory loss associated with the disease.
SNIFF
The purpose of the SNIFF study is to find out whether a type of insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer’s disease (AD). The study enrolled 250 adults, age 55-85 who were diagnosed with amnestic mild cognitive impairment (aMCI) or early AD. There were 26 clinical sites involved. Scientists have learned that MCI has several subtypes. In the most common subtype with high probability of progression to Alzheimer’s disease, memory loss is the most prominent feature (other types of MCI feature other types of cognitive problems).
Connect
The Connect study tested whether an oral, experimental drug, AZD0530 (saracatinib), would slow progression in early stage Alzheimer’s disease (AD). In its early stage after the medical diagnosis of Alzheimer’s disease, patients typically show some memory loss, but a majority of daily functions are intact, requiring some reminders or help organizing the day from others in the household. The University of Southern California, Alzheimer’s Therapeutic Research Institute served as the coordinating center, helping to enroll 159 participants at 23 clinical sites across the United States.
DOD ADNI
The purpose of DOD ADNI is to examine the possible connections between Traumatic Brain Injury (TBI) and Posttraumatic Stress Disorder (PTSD), and the signs and symptoms of AD on Veterans as they age. Approximately 300 Vietnam War Veterans, ages 50-90 will be eligible to participate in this study
EARLY Trial
The EARLY Trial was looking to determine the Efficacy and safety of atabecestat in participants who are Asymptomatic at Risk for developing Alzheimer’s dementia. The study sponsor, Janssen, sought to use the latest advances to assess a participant’s risk associated with beta-amyloid and memory loss, and test whether a treatment that reduces amyloid formation would slow memory loss associated with Alzheimer’s disease (AD).
Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD)
Those identified to have a potential increased risk for memory loss caused by Alzheimer’s disease were referred from the APT Webstudy (above) to the Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD) in-person study. The purpose of TRC-PAD was to find as many people as possible (also called a “cohort”) who were interested in participating in clinical trials aimed at discovering treatments to reduce the risk of developing Alzheimer’s dementia. TRC-PAD sought to help researchers enroll participants into these trials quickly to allow new treatments to be discovered as soon as possible.